Mode
Text Size
Log in / Sign up

Migraine

Subtypes of Migraine

Episodic Migraine 3 Vestibular migraine 2 Abdominal migraine 1 Migraine with or without aura 0

17 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Migraine

220 trials tracked for Migraine: 118 in phase 3 or 4 and 55 with published results. The most-cited published study has 350 citations.

220Trials tracked
118Phase 3 & 4
0Recruiting
55With published results
Phase distribution
Phase 4 50 Phase 3 68 Phase 2 32 Phase 1 16 Other / NA 54
  1. Phase 3 Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults Completed · 350 cited
  2. Phase 4 Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine Completed · 177 cited
  3. Phase 3 Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine Completed · 176 cited
  4. Phase 3 Randomized Trial in Adult Participants With Acute Migraines Completed · 144 cited
  5. Phase 3 A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura Completed · 141 cited
  6. Phase 3 Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine Completed · 129 cited
Show 44 more trials
  1. Phase 3 A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine Completed · 103 cited
  2. Phase 3 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention Completed · 96 cited
  3. Phase 3 Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants Completed · 83 cited
  4. Phase 4 Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine Completed · 79 cited
  5. Phase 3 Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine Completed · 70 cited
  6. Phase 3 Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine Completed · 67 cited
  7. Phase 3 Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura Completed · 54 cited
  8. Phase 4 Diphenhydramine for Acute Migraine Completed · 47 cited
  9. Phase 3 Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study Completed · 43 cited
  10. Phase 3 Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study Completed · 43 cited
  11. Phase 4 A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine Completed · 41 cited
  12. Phase 3 Evaluation of Galcanezumab in the Prevention of Chronic Migraine Completed · 41 cited
  13. Phase 3 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention Completed · 41 cited
  14. Phase 4 Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action Completed · 37 cited
  15. Phase 3 A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine Completed · 32 cited
  16. Phase 4 Imaging the Migraine Brain Pre- and Post-Erenumab Completed · 31 cited
  17. Phase 4 Ticagrelor Therapy for RefrACTORy Migraine Study Completed · 30 cited
  18. Phase 3 Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients Completed · 30 cited
  19. Phase 3 Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine Completed · 29 cited
  20. Phase 3 A Study of Lasmiditan (LY573144) Over Four Migraine Attacks Completed · 26 cited
  21. Phase 3 DFN-02 Open Label Safety Study in Patients With Acute Migraine Completed · 24 cited
  22. Phase 4 Effect of Acetyl-L-carnitine in Migraine Completed · 23 cited
  23. Phase 3 A Controlled Trial of Erenumab in Migraine Prevention Completed · 22 cited
  24. Phase 3 Lasmiditan Compared to Placebo in the Acute Treatment of Migraine: Completed · 21 cited
  25. Phase 4 Corticosteroids for Acute Migraine in the Emergency Department Completed · 20 cited
  26. Phase 4 A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder Completed · 18 cited
  27. Phase 3 Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine Completed · 17 cited
  28. Phase 4 Biomarker and Genetic Predictors of Erenumab Treatment Response Completed · 15 cited
  29. Phase 3 A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine Completed · 15 cited
  30. Phase 3 A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine Completed · 14 cited
  31. Phase 3 Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine Completed · 14 cited
  32. Phase 3 Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine Completed · 14 cited
  33. Phase 4 Treatment of Insomnia in Migraineurs Completed · 13 cited
  34. Phase 3 Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only) Completed · 12 cited
  35. Phase 3 Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine Completed · 10 cited
  36. Phase 3 Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine Completed · 10 cited
  37. Phase 4 Dexamethasone for Migraine - Dose Comparison Completed · 9 cited
  38. Phase 3 Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only) Completed · 7 cited
  39. Phase 3 A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age Completed · 7 cited
  40. Phase 3 A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine Completed · 5 cited
  41. Phase 4 Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Completed · 4 cited
  42. Phase 4 Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications Completed · 4 cited
  43. Phase 3 A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments Completed · 4 cited
  44. Phase 4 Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use Completed · 3 cited

Showing the 50 most-cited and recently-updated of 220 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Questions about Migraine

What are the real-world results of using eptinezumab for ongoing episodic or chronic migraine attacks?

Real-world data from the BE-FREE study shows that eptinezumab reduces pain intensity and associated symptoms like light sensitivity within 10 to 20 minutes of infusion for patients with ongoing migraine attacks.

Full answer →
Does eptinezumab plus education reduce migraine days in chronic migraine patients who overuse medication?

Yes, a 12-week trial found that eptinezumab combined with a brief educational intervention reduced monthly migraine days in adults with chronic migraine and medication overuse.

Full answer →
How does resting-state fMRI show brain entropy differences in chronic migraine compared to healthy controls?

Resting-state fMRI shows that people with chronic migraine have lower brain entropy in key brain networks compared to healthy people, and this difference is even greater in chronic migraine than in episodic migraine.

Full answer →
Does intravenous eptinezumab help reduce pain and symptoms during an ongoing chronic migraine attack?

Yes, intravenous eptinezumab can reduce pain and symptoms during an ongoing chronic migraine attack, with effects seen within 10-30 minutes of infusion.

Full answer →
Does resting-state fMRI show different brain activity in people with chronic migraine?

Yes, resting-state fMRI shows reduced brain entropy and altered low-frequency brain activity in people with chronic migraine compared to healthy controls.

Full answer →
Can a smartphone app accurately predict when my migraine attacks will happen?

Smartphone apps can provide short-term predictions for migraine attacks, but current models only predict about a 59% chance of an attack occurring within 24 hours, which is only slightly better than random guessing.

Full answer →
See all 6 questions about Migraine →